SCHEMBL24313896

SCHEMBL24313896

CC(C)c1ccc2cc(C(=O)O)oc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 5/20 0.50
CSNK2A1 P68400 4/20 0.50
CSNK2A2 P19784 3/20 0.50
CSNK2B P67870 3/20 0.50
CSNK2A3 Q8NEV1 3/20 0.50
EIF4A3 P38919 1/20 0.46
IKBKE Q14164 2/20 0.46
TBK1 Q9UHD2 2/20 0.46
THRB P10828 2/20 0.46
THRA P10827 1/20 0.46
FLT3 P36888 1/20 0.45
LMNA P02545 2/20 0.44
ALDH1A1 P00352 2/20 0.44
TP53 P04637 1/20 0.44
KDM4E B2RXH2 4/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
GLA P06280 1/20 0.44
MAPT P10636 1/20 0.44
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12869441 0.87 PIM1 (0.58) PIM1CSNK2A1CSNK2A2CSNK2BCSNK2A3
SCHEMBL31723085 0.87 FLT3 (0.45) EIF4A3IKBKETBK1THRBFLT3
SCHEMBL5557517 0.78 ALDH1A1 (0.63) PIM1CSNK2A1CSNK2A2CSNK2BCSNK2A3
SCHEMBL5599845 0.77 PIM1 (0.54) PIM1CSNK2A1CSNK2A2CSNK2BCSNK2A3
SCHEMBL24313655 0.76 BCAT1 (0.53) THRBLMNAALDH1A1KDM4ENPC1
Hydrochloric Acid SCHEMBL11744549 0.76 PIM1 (0.53) PIM1CSNK2A1CSNK2A2CSNK2BCSNK2A3
SCHEMBL6407371 0.75 FLT3 (0.76) PIM1CSNK2A1CSNK2A2CSNK2BCSNK2A3
SCHEMBL28044374 0.75 PIM1 (0.56) PIM1CSNK2A1CSNK2A2CSNK2BCSNK2A3
SCHEMBL24313654 0.75 ALDH1A1 (0.47) THRBLMNAALDH1A1TP53MAPT
SCHEMBL24138422 0.75 PIM1 (0.51) PIM1CSNK2A1CSNK2A2CSNK2BCSNK2A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4229045-B1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER BROAD INST INC (US) 2025-11-12 EP disclosed
US-20240287048-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER BAYER AKTIENGESELLSCHAFT (DE) 2024-08-29 US disclosed
EP-4229045-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER The Broad Institute Inc. (US) 2023-08-23 EP disclosed
US-20230117680-A1 CYCLOPHILIN D INHIBITORS AND USES THEREOF THE BROAD INSTITUTE, INC. (US) 2023-04-20 US disclosed
WO-2022081842-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER THE BROAD INSTITUTE, INC. (US) 2022-04-21 WO disclosed
WO-2022081842-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER THE BROAD INSTITUTE, INC. (US) 2022-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287048-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER KAT6A, KAT6B, KAT2A PIM1 1899/4885CSNK2A1 410/4885CSNK2A2 421/4885
US-20230117680-A1 CYCLOPHILIN D INHIBITORS AND USES THEREOF PPID, PPIF, PPIL1 PIM1 3111/4885CSNK2A1 3790/4885CSNK2A2 4013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.